Amidine-modified Leu-enkephalin enhances μ-opioid receptor G-protein signaling while boosting proteolytic stability

The therapeutic potential of peptides is often severely limited by rapid degradation mediated by endogenous proteases, leading to short half-lives and reduced bioavailability. Traditional strategies to enhance peptide stability frequently compromise their native conformation or physicochemical properties, negatively impacting pharmacological profiles. This research addresses a critical gap by exploring a minimal, site-specific modification that can confer protease resistance without requiring extensive scaffold redesign, thereby preserving or even improving the peptide's intrinsic activity. The goal is to develop more robust and effective peptide therapeutics.

Researchers investigated backbone amidine substitution as a novel, site-specific modification to enhance peptide metabolic stability. They utilized the pentapeptide Leu-enkephalin as a model system to demonstrate this strategy. Specific amidine analogs were synthesized, where metabolically labile amide bonds were replaced with amidine linkages. The study evaluated the position-dependent effects of these modifications on proteolytic stability. Furthermore, the pharmacological profile of one promising amidine analog was assessed, specifically its G-protein signaling and β-arrestin2 recruitment at the μ-opioid receptor.

Amidine replacement of metabolically labile amides in Leu-enkephalin successfully attenuated or blocked proteolysis in a position-dependent manner, significantly enhancing the peptide's metabolic stability. This demonstrates the efficacy of amidine substitution in conferring protease resistance.

One specific amidine analog not only preserved but also remarkably enhanced G-protein signaling at the μ-opioid receptor. This enhanced G-protein signaling was coupled with a reduction in β-arrestin2 recruitment, a key finding as β-arrestin2 is often implicated in receptor desensitization and adverse effects of opioid agonists. The modification thus offers a dual benefit: improved stability and a favorable signaling bias towards G-protein activation, which could lead to more effective and potentially safer therapeutic profiles.